PROLOR Biotech (PBTH) announces that it achieved positive top-line results from a study of its human growth hormone tested in a Phase II clinical study. The results indicate the firm's drug may be able to achieve the same results as currently marketed treatments with fewer injections required. Shares +3.8% premarket.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs